🔎 Trials Near Me

Home › Cancer (all types) › NCT07019259

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors

Recruiting

Who can join

Ages 5 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* History of childhood cancer (\<21 years of age at diagnosis)
* Current age five years or older (due to availability of validated measures for CIPN in this age group)
* History of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN
* CIPN as assessed by a trained physical therapist defined as a score of four or higher on the ped-mTNS (for survivors \<18 years old at evaluation), or the mTNS (for survivors 18 years or older at evaluation)

Exclusion Criteria:

* Currently Pregnant or lactating (by patient report, at initiation or at any point of the study)
* Inability to sit still for at least 15 minutes
* Diagnosis of neuropathy prior to cancer treatment
* Active cancer diagnosis or cancerous skin lesion
* Central nervous system tumor (due to lack of validated measures for CIPN in this population)
* Cancer lesion or open wound in the area to be treated, or any condition that can potentially be made worse by the correct or incorrect use of the device.

About the study

The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.

What is being tested

Sponsor: Yale University · Participants: 20 · Started: Jun 30, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07019259

Locations in the U.S.

ConnecticutYale New Haven Health Smilow York Street Hospital, New Haven
Yale New Haven Health Park Avenue Medical Center, Trumbull

Conditions

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.